Access our webinar: Tumor fusion burden and the immune landscape of prostate cancer

 The webinar in brief

• We discuss how immune checkpoint inhibitors have been largely unsuccessful against prostate cancer, and current biomarkers do not effectively identify those patients most likely to respond to treatment
• This presentation explores what the genetic make-up of a tumor can tell us about its immune landscape, and describes tumor fusion burden, a novel biomarker for immune cell infiltration and activation in prostate cancer

Fill the form below to access: